-
2
-
-
0035289220
-
Update on chemotherapy for advanced colorectal cancer
-
Haller DG. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt). 2001; 15: 11-5.
-
(2001)
Oncology (Huntingt)
, vol.15
, pp. 11-15
-
-
Haller, D.G.1
-
4
-
-
0035281522
-
Irinotecan in the treatment of colorectal cancer: Clinical overview
-
Vanhoefer U, Harstrick A, Achterrath W., Cao S, Seeber S, Rustum YM Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19: 1501-18.
-
(2001)
J Clin Oncol.
, vol.19
, pp. 1501-1518
-
-
Vanhoefer, U.1
Harstrick, A.2
Achterrath, W.3
Cao, S.4
Seeber, S.5
Rustum, Y.M.6
-
5
-
-
0036304427
-
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins
-
García-Carbonero R., Supko JG Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002; 8: 641-61.
-
(2002)
Clin Cancer Res.
, vol.8
, pp. 641-661
-
-
García-Carbonero, R.1
Supko, J.G.2
-
6
-
-
0027140524
-
Phase I and pharmacokinetic trial of weekly CPT-11
-
Rothenberg ML, Kuhn JG, Burris H.A., et al Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993; 11: 2194-204.
-
(1993)
J Clin Oncol.
, vol.11
, pp. 2194-2204
-
-
Rothenberg, M.L.1
Kuhn, J.G.2
Burris, H.A.3
-
7
-
-
0028854897
-
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
-
Abigerges D, Chabot GG, Armand J.P., Herait P., Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995; 13: 210-21.
-
(1995)
J Clin Oncol.
, vol.13
, pp. 210-221
-
-
Abigerges, D.1
Chabot, G.G.2
Armand, J.P.3
Herait, P.4
Gouyette, A.5
Gandia, D.6
-
8
-
-
0025851286
-
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
-
Negoro S, Fukuoka M, Masuda N., et al Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 1164-8.
-
(1991)
J Natl Cancer Inst.
, vol.83
, pp. 1164-1168
-
-
Negoro, S.1
Fukuoka, M.2
Masuda, N.3
-
9
-
-
0035695192
-
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
-
Rothenberg ML, Kuhn JG, Schaaf L.J., et al Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001; 12: 1631-41.
-
(2001)
Ann Oncol.
, vol.12
, pp. 1631-1641
-
-
Rothenberg, M.L.1
Kuhn, J.G.2
Schaaf, L.J.3
-
10
-
-
0034568428
-
Chemoprotective and radioprotective effects of amifostine: An update of clinical trials
-
Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000; 72: 425-35.
-
(2000)
Int J Hematol.
, vol.72
, pp. 425-435
-
-
Capizzi, R.L.1
Oster, W.2
-
11
-
-
0037089642
-
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma
-
Delioukina ML, Prager D, Parson M., Hecht JR, Rosen P, Rosen LS Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 2002; 94: 2174-9.
-
(2002)
Cancer
, vol.94
, pp. 2174-2179
-
-
Delioukina, M.L.1
Prager, D.2
Parson, M.3
Hecht, J.R.4
Rosen, P.5
Rosen, L.S.6
-
13
-
-
0037540807
-
-
National Cancer Institute MD, Division of Cancer Treatment, National Cancer Institute
-
National Cancer Institute. Guidelines for the reporting of adverse drug reactions. MD, Division of Cancer Treatment, National Cancer Institute; 1999: 1-80.
-
(1999)
Guidelines for the Reporting of Adverse Drug Reactions
, pp. 1-80
-
-
-
15
-
-
0033053920
-
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
-
Van Cutsem E., Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer. 1999; 35: 54-9.
-
(1999)
Eur J Cancer
, vol.35
, pp. 54-59
-
-
Van Cutsem, E.1
Cunningham, D.2
Ten Bokkel Huinink, W.W.3
-
16
-
-
84873476033
-
Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: A multicenter phase II study
-
Navarro M, Losa F, Manzano H., et al Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study. Rev Oncol. 2002; 4: 385-90.
-
(2002)
Rev Oncol.
, vol.4
, pp. 385-390
-
-
Navarro, M.1
Losa, F.2
Manzano, H.3
-
17
-
-
10744226030
-
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): A phase II study
-
Anton A, Aranda E, Carrato A., et al Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol. 2003; 25: 639-43.
-
(2003)
Methods Find Exp Clin Pharmacol.
, vol.25
, pp. 639-643
-
-
Anton, A.1
Aranda, E.2
Carrato, A.3
-
18
-
-
0034727063
-
Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group
-
Saltz LB, Cox JV, Blanke C, et al Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-14.
-
(2000)
N Engl J Med.
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
19
-
-
0031014627
-
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretre-ated with fluorouracil-based chemotherapy
-
Rougier P, Bugat R, Douillard J.Y., et al Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretre-ated with fluorouracil-based chemotherapy. J Clin Oncol. 1997; 15: 251-60.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 251-260
-
-
Rougier, P.1
Bugat, R.2
Douillard, J.Y.3
-
20
-
-
0032585232
-
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
-
Cunningham D, Pyrhonen S, James R.D., et al Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-8.
-
(1998)
Lancet
, vol.352
, pp. 1413-1418
-
-
Cunningham, D.1
Pyrhonen, S.2
James, R.D.3
-
21
-
-
0032585197
-
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
-
Rougier P, Van Cutsem E, Bajetta E, et al Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 1407-12.
-
(1998)
Lancet
, vol.352
, pp. 1407-1412
-
-
Rougier, P.1
Van Cutsem, E.2
Bajetta, E.3
-
22
-
-
0033558004
-
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
-
Rothenberg ML, Cox JV, DeVore R.F., et al A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999; 85: 786-95.
-
(1999)
Cancer
, vol.85
, pp. 786-795
-
-
Rothenberg, M.L.1
Cox, J.V.2
DeVore, R.F.3
-
23
-
-
0030818926
-
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
-
Pitot HC, Wender DB, O'Connell MJ, et al Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997; 15: 2910-9.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 2910-2919
-
-
Pitot, H.C.1
Wender, D.B.2
O'Connell, M.J.3
-
24
-
-
0345375527
-
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination
-
Tsavaris N, Ziras N, Kosmas C., et al Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. Cancer Chemother Pharmacol. 2003; 52: 514-9.
-
(2003)
Cancer Chemother Pharmacol.
, vol.52
, pp. 514-519
-
-
Tsavaris, N.1
Ziras, N.2
Kosmas, C.3
-
25
-
-
0036605387
-
Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial
-
Souglakos J, Mavroudis D, Kakolyris S., et al Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 2002; 20: 2651-7
-
(2002)
J Clin Oncol.
, vol.20
, pp. 2651-2657
-
-
Souglakos, J.1
Mavroudis, D.2
Kakolyris, S.3
-
26
-
-
0035990069
-
Addition of either irinotecan or methotrexate to bolus 5-fluoruracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the southern Italy cooperative oncology group
-
Comella P, Crucitta E, De Vita L, et al Addition of either irinotecan or methotrexate to bolus 5-fluoruracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Annals Oncol. 2002; 13: 866-73.
-
(2002)
Annals Oncol.
, vol.13
, pp. 866-873
-
-
Comella, P.1
Crucitta, E.2
De Vita, L.3
|